| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Mentoring Future Leaders: A Five-Step Formal Mentor System For Your Organization! |
|
Digg It - Mentoring Future Leaders: A Five-Step Formal Mentor System For Your Organization!
“When the student is ready, the teacher will reveal themselves.”
- Unknown, as told by Jim Stovall, CEO, Narrative Television Network Where have all the leaders gone? How do you cultivate a leader wit According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product hin? In today’s demanding work environment everyone must have a little leader within themselves and at times a real leader is needed to step forward and lead others to greatness. To do so, takes an act ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ive and systematic approach to developing those within an organization. A model for an effective “Leadership Mentor Development Program” may incorporate a five-step approach. 1. Mentor Level One – woul lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. be an elementary mentor, whereby the mentor possess great basic knowledge and patience of a subject matter, which needs to be instilled into another person. 2. Mentor Level Two – would be the graduati here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe on of the mentee to a secondary mentor whom can provide opportunities to the mentee to apply this new knowledge or skill. This secondary mentor serves as a contact person for the mentee while they are b d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ing drilled in the application of this knowledge and assists them in becoming both comfortable and proficient with this knowledge base. 3. Mentor Level Three – would be a post secondary mentor that has ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc the capacity to challenge the mentee constructively to seek new applications for this basic knowledge base and encourages them to seek greatness with it. 4. Mentor Level Four – would be a master mento easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi , that person whom has a well positioned network of stakeholders and decision makers across organizational lines that can serve to promote and sale the mentee to others, unbeknownst to them! 5. Mentor nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically Level Five – would be that level which a mentee has been grown and developed from level one through level four and now that mentee has demonstrated a grasp and application of knowledge and experience an and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ has therefore earned the right to become a mentor themselves and grow another person. Now the process reverses, with a reverse mentor relationship ability! This model may serve as a powerful template ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi to dictate very specifically what the responsibilities may be for each level in the mentor-to-mentee development life cycle. Another critical question lies with who has the right to serve as a mentor, ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a now that there is an objective means of how to measure the developmental progress of a mentee. First level considerations in selecting, recruiting or accepting nominations/applications for mentors is: dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod . A willingness on the part of the mentor to invest ones’ time and energy into the mentee is critical for this growth relationship to develop present and future leaders for organizations today. 2. A re cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin servoir of knowledge by the mentor, both in terms of formal and informal knowledge/training/skill attainment/certifications, that can be deposited into a willing mentee and thus enable a shorten learnin tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen curve to develop! 3. An accomplished and dedicated senior member who may be of the present mindset that because of their tenure they are no longer valued and appreciated can be an ideal candidate and t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel this participation opportunity may be just the prescription for a renewed energy. 4. A person with genuine vested interest in the organizations success and core survival will be an exceedingly diligent ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust mentor and take the mentee’s interest to heart. A fast track to “Leadership Mentor Development Program” failure is expecting or accepting any individual into participation that do not adhere to any of y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products the above benchmark suggestions. An Ohio State University study indicated that professional women in the work place with mentor relationships were as much as 68 times more promotable and marketable in . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de heir careers among individuals with no mentor relationships. The question for organizations and for managerial-leaders to ask now is, “can we afford not to invest in our personnel asset by not having a elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip mentor program?” “If a man empties his pyres into his head, no one can take it away from him. An investment in knowledge always pays the best interest.” - Benjamin Franklin, Inventor, Statesman, Write tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Medical Billing: To Save Or To Insure An Introduction to Motivational Speaking Important Facets of the Medical Transcription Profession – Part 1
|